Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 2c, Miss on Revenues

Note: EPS may not be comparable

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.80), $0.02 worse than the analyst estimate of ($0.78). Revenue for the quarter came in at $1.19 million versus the consensus estimate of $1.65 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral